Cardiac Amyloid Load: A Prognostic and Predictive Biomarker in Patients With Light-Chain Amyloidosis
- PMID: 27364045
- DOI: 10.1016/j.jacc.2016.04.035
Cardiac Amyloid Load: A Prognostic and Predictive Biomarker in Patients With Light-Chain Amyloidosis
Abstract
Background: Cardiac amyloid load has not been analyzed for its effect on mortality in patients with amyloid light-chain (AL) cardiac amyloidosis.
Objectives: This study retrospectively compared histological amyloid load with common clinical predictors of mortality.
Methods: This study assessed 216 patients with histologically confirmed cardiac amyloidosis at a single center with electrocardiography, echocardiography, and laboratory testing.
Results: AL amyloid deposits were usually distributed in a reticular/pericellular pattern, whereas transthyretin amyloid (ATTR) more commonly showed patchy deposits. Median amyloid load was 30.5%; no amyloid load was above 70%. During follow-up (median 19.1 months), 112 patients died. Chemotherapy had a significant effect on overall survival in AL amyloidosis (16.2 months vs. 1.4 months; p = 0.003). Patients with <20% AL amyloid load who responded to chemotherapy showed significantly better survival than nonresponders. According to univariate analysis, predictors of survival in AL amyloidosis included sex, Karnofsky index, New York Heart Association (NYHA) functional class, diastolic blood pressure, estimated glomerular filtration rate, N-terminal pro-B-type natriuretic peptide, mineralocorticoid receptor antagonists, low voltage, ineligibility for chemotherapy, response to chemotherapy, and amyloid load. Independent predictors of mortality by multivariate analysis included NYHA functional class (III vs. II), estimated glomerular filtration rate, responders to chemotherapy, and amyloid load. In ATTR amyloidosis, survival correlated with NYHA functional class, diastolic blood pressure, and use of diuretic agents. Following Cox regression analysis, NYHA functional class (III vs. II; p < 0.05) remained the only independent predictor of patient survival in ATTR amyloidosis.
Conclusions: Early identification of subjects with AL amyloid is essential given that in late-stage disease with extensive amyloid load, our data suggested that outcomes are not affected by administration of chemotherapy.
Keywords: amyloidosis; endomyocardial biopsy; immunohistochemistry; light-chain amyloid; survival; transthyretin.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Amyloid Cardiomyopathy.J Am Coll Cardiol. 2016 Jul 5;68(1):25-8. doi: 10.1016/j.jacc.2016.05.009. J Am Coll Cardiol. 2016. PMID: 27364046 No abstract available.
-
Should Histologic Determination of Amyloid Load Determine Management Decisions in Light-Chain Amyloidosis?J Am Coll Cardiol. 2016 Dec 6;68(22):2493-2494. doi: 10.1016/j.jacc.2016.07.786. J Am Coll Cardiol. 2016. PMID: 27908360 No abstract available.
-
Reply: Should Histologic Determination of Amyloid Load Determine Management Decisions in Light-Chain Amyloidosis?J Am Coll Cardiol. 2016 Dec 6;68(22):2494-2495. doi: 10.1016/j.jacc.2016.08.068. J Am Coll Cardiol. 2016. PMID: 27908361 No abstract available.
Similar articles
-
[Cardiac amyloidosis: pathological classification and clinical analysis of 48 cases].Zhonghua Bing Li Xue Za Zhi. 2023 Jul 8;52(7):671-677. doi: 10.3760/cma.j.cn112151-20221230-01082. Zhonghua Bing Li Xue Za Zhi. 2023. PMID: 37408396 Review. Chinese.
-
Predictors of survival stratification in patients with wild-type cardiac amyloidosis.Clin Res Cardiol. 2018 Feb;107(2):158-169. doi: 10.1007/s00392-017-1167-1. Epub 2017 Sep 27. Clin Res Cardiol. 2018. PMID: 28956153
-
Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.J Am Heart Assoc. 2016 Mar 24;5(3):e002877. doi: 10.1161/JAHA.115.002877. J Am Heart Assoc. 2016. PMID: 27013539 Free PMC article.
-
Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis.JACC Cardiovasc Imaging. 2016 Feb;9(2):126-38. doi: 10.1016/j.jcmg.2015.05.014. Epub 2016 Jan 6. JACC Cardiovasc Imaging. 2016. PMID: 26777222
-
Cardiac amyloidosis: updates in diagnosis and management.Arch Cardiovasc Dis. 2013 Oct;106(10):528-40. doi: 10.1016/j.acvd.2013.06.051. Epub 2013 Sep 23. Arch Cardiovasc Dis. 2013. PMID: 24070600 Review.
Cited by
-
Pre-test Prediction of Non-ischemic Cardiomyopathies using Time-Series EHR Data.AMIA Jt Summits Transl Sci Proc. 2024 May 31;2024:239-248. eCollection 2024. AMIA Jt Summits Transl Sci Proc. 2024. PMID: 38827049 Free PMC article.
-
Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment-67 Patients Multicenter Analysis.Cancers (Basel). 2024 Apr 21;16(8):1592. doi: 10.3390/cancers16081592. Cancers (Basel). 2024. PMID: 38672674 Free PMC article.
-
High-Sensitivity Cardiac Troponin T to Exclude Cardiac Involvement in TTR Variant Carriers and ATTRv Amyloidosis Patients.J Clin Med. 2024 Jan 30;13(3):810. doi: 10.3390/jcm13030810. J Clin Med. 2024. PMID: 38337504 Free PMC article.
-
Development and characterization of a prototypic pan-amyloid clearing agent - a novel murine peptide-immunoglobulin fusion.Front Immunol. 2023 Oct 2;14:1275372. doi: 10.3389/fimmu.2023.1275372. eCollection 2023. Front Immunol. 2023. PMID: 37854603 Free PMC article.
-
Prognosis of light chain amyloidosis: a multivariable analysis for survival prediction in patients with cardiac involvement proven by endomyocardial biopsy.Open Heart. 2023 Jul;10(2):e002310. doi: 10.1136/openhrt-2023-002310. Open Heart. 2023. PMID: 37463823 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials